CorTec Receives FDA Breakthrough Device Designation for Brain-Computer Interface in Stroke Rehabilitation
核心洞察
CorTec GmbH (搜索) has received FDA Breakthrough Device Designation for its Brain Interchange (搜索) system, marking the first BCI worldwide designated specifically for stroke (搜索) motor rehabilitation.
The fully implantable, wireless system combines neural signal recording with adaptive stimulation in a closed-loop design and is currently being evaluated in the first human clinical trial at the University of Washington.
With approximately 9 million ischemic strokes occurring globally each year and over 50% of survivors remaining permanently disabled despite standard rehabilitation, the designation addresses a significant unmet medical need.
CorTec GmbH (搜索), a German neurotechnology company, has achieved a significant regulatory milestone with the U.S. Food and Drug Administration granting Breakthrough Device Designation for its Brain Interchange (搜索) system. The designation specifically covers the use of direct cortical electrical stimulation to support motor recovery in people living with chronic stroke (搜索)-related impairments, making it the first brain-computer interface worldwide to receive this designation for stroke motor rehabilitation.
The FDA's Breakthrough Device Designation is reserved for medical technologies that demonstrate the potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions. This status provides CorTec with an accelerated regulatory pathway, including prioritized review and enhanced access to FDA experts during development and pre-market approval stages.
Addressing Critical Unmet Medical Need
Stroke (搜索) represents a massive global health challenge, serving as the leading cause of acquired long-term disability in adults worldwide. Approximately 9 million ischemic strokes occur globally each year, with an estimated 1.7 million cases in the United States and Europe alone. The clinical burden is substantial: over 80% of stroke patients experience upper-limb impairment, and approximately 50% remain permanently disabled despite standard rehabilitation.
For chronic stroke (搜索) patients with moderate-to-severe motor deficits whose recovery has plateaued after conventional therapy, no approved implantable treatment currently exists. This represents a significant gap in therapeutic options for a vulnerable patient population.
Innovative Closed-Loop Technology
CorTec's Brain Interchange (搜索) system distinguishes itself through its fully implantable, wireless design that combines neural signal recording with adaptive stimulation in a closed-loop configuration. The platform is currently being evaluated in an FDA-approved Investigational Device Exemption study at the University of Washington in Seattle, marking the first clinical investigation of a fully implantable, wireless BCI system for stroke (搜索) rehabilitation in humans.
The system has demonstrated remarkable stability, with published data in Nature Scientific Data showing signal stability over 500 days of continuous operation. Initial clinical results have been promising, with the first patient showing meaningful neurological improvement, including recovery of upper-limb motor function that had previously plateaued with conventional therapy.
Unique Market Position
"Only a few BCI companies worldwide – including Neuralink (搜索), Synchron (搜索), or Blackrock Neurotech (搜索) – have received Breakthrough Device Designation to date," said Dr. Frank Desiere, CEO of CorTec. "Achieving this designation is a defining milestone for CorTec and underscores the potential of our Brain Interchange (搜索) system to address the significant unmet need in stroke (搜索) rehabilitation."
CorTec's approach represents a distinct direction within the global BCI field. While other BCI systems that have received Breakthrough Device Designation are primarily focused on enabling patient communication by controlling digital devices through thought, the Brain Interchange (搜索) platform is being developed as a therapeutic device that enables neurostimulation to physically restore motor function. At present, no other BCI company worldwide holds a Breakthrough Device Designation for this specific indication.
Regulatory Strategy and Clinical Development
The company has followed a systematic regulatory approach, beginning with FDA 510(k) clearance for cortical mapping electrodes in 2019. CorTec demonstrated the first successful beta-phase–locked closed-loop stimulation in a 2023 feasibility study at the University of Washington. Following Investigational Device Exemption approval in 2024, the first two patients were implanted at Harborview Medical Center in Seattle in July 2025 and February 2026.
"The Breakthrough Device Designation enables more frequent and structured engagement with the FDA as we advance our development program," said Mara Assis, Head of Regulatory Affairs & Quality Management at CorTec. "Our regulatory strategy has followed a stepwise approach, from prior device clearance to IDE approval and successful human implantations. This designation will help accelerate planning of clinical trials and support the next regulatory milestones."
Multi-Indication Platform Potential
Beyond stroke (搜索) rehabilitation, CorTec continues to advance the Brain Interchange (搜索) System as a flexible, adaptive platform with potential applications across multiple neurological conditions. The platform is currently being evaluated for epilepsy (搜索) in an FDA-registered study at Mayo Clinic, with further indications including paralysis (搜索) and depression (搜索) under development.
The company operates a dual business model comprising its proprietary Brain Interchange (搜索) BCI platform and a growing contract development and manufacturing division. Founded in 2010 in Freiburg, Germany, CorTec is the first European company to bring a fully implantable, bidirectional BCI system into FDA-approved clinical evaluation in the United States.